fda tirzepatide news approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly The FDA says the Zepbound

1 Introduction Cardiovascular disease (CVD) continues to be a significant global health concern, with ischemic stroke and acute myocardial infarction ranking as the second and third leading causes of death worldwide in 2019 ( The complex interaction between diabetes mellitus (DM) and cardiovascular events complicates patient management

Of course, if the FDA doesnt grant a new indication, that doesnt mean Lilly and BI will go home empty-handed

Knowing this can make it easier to plan meals, exercise, and other daily routines

Furthermore, the FDA has issued warnings regarding mass-marketed, non-FDA-approved compounded GLP-1 alternatives

Long-term safety studies, however, have not been conducted (see Concerns and Cautions)